VBI Vaccines' three-antigen HBV vaccine shows positive action in late-stage studies

• VBI Vaccines (NASDAQ:VBIV) announces the presentation of abstracts at the ID Week conference from two Phase 3 clinical trials, PROTECT and CONSTANT, evaluating Sci-B-Vac, its three-antigen prophylactic hepatitis B virus (HBV) vaccine.
• Higher hepatitis B antibody titers were induced in all adults receiving Sci-B-Vac compared to a single-antigen vaccine. Specifically, antibody titers were 6x higher than GlaxoSmithKline's (NYSE:GSK) Engerix-B. The increase was sustained across key subgroups including older adults, diabetics and obese individuals.
• Joanne Langley, M.D., Professor of Pediatrics and Community Health and Epidemiology, CIHR-GSK Chair in Pediatric Vaccinology, Dalhousie University, and Head of the Division of Infectious Disease, IWK Health Centre, and principal investigator of the PROTECT study says, "Currently licensed HBV vaccines such as Engerix-B have important limitations. These include reduced immunogenicity in certain subgroup populations such as adults over 45, diabetics, and persons with obesity. The results from this Phase 3 clinical program clearly demonstrate Sci-B-Vac’s ability to safely induce rapid and robust immune responses in young adults, as well as in older adults and those with comorbidities – a significant improvement upon Engerix-B."
• Results from PROTECT were first announced in June 2019. Results from CONSTANT were announced in January of this year.
• Marketing applications in the U.S., Europe and Canada are next up.
• https://seekingalpha.com/news/3625716-vbi-vaccines-three-antigen-hbv-vaccine-shows-positive-action-in-late-stage-studies